Last checked at 
July 28 (Reuters) - Hikma Pharmaceuticals Plc saidit would buy German drugmaker Boehringer Ingelheim's U.S.specialty generic drugs business for about $2.65 billion in cashand stock to bolster its presence in the United States.
Hikma said it will pay about $1.18 billion in cash and issue40 million new Hikma shares, or about 16.71 per cent of itsissued share capital, for Boehringer's Roxane Laboratories Incand Boehringer Ingelheim Roxane Inc on closing of the deal.
The company said the deal valuation was based on an agreedissue price for the new Hikma shares of 23.50 pounds per shareand an exchange rate of 1.56 dollars to the pound.
Hikma has also agreed to make milestone payments of up to$125 million. (Reporting by Roshni Menon in Bengaluru; Editing by AnupamaDwivedi)
